Probiotics for the treatment of inflammatory bowel disease (Q38009716)

26 August 2017

title

Probiotics for the treatment of inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

26 August 2017

main subject

0 references

0 references

0 references

Ganesh R Veerappan

1

1 reference

26 August 2017

John Betteridge

series ordinal

2

1 reference

26 August 2017

Patrick E Young

series ordinal

3

1 reference

26 August 2017

language of work or name

1 reference

1 August 2012

1 reference

Current gastroenterology reports

26 August 2017

published in

1 reference

26 August 2017

volume

14

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

324-333

1 reference

Inflammatory Bowel Disease

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Unravelling the pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Development of the human infant intestinal microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Gut flora in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

The host-microbe interface within the gut

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Colitis in transgenic and knockout animals as models of human inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

New concepts in the pathophysiology of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Role of the faecal stream in the maintenance of Crohn's colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Effects of the faecal stream and stasis on the ileal pouch mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Mucosal flora in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Pouchitis: result of microbial imbalance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Potential probiotic characteristics of Lactobacillus and Enterococcus strains isolated from traditional dadih fermented milk against pathogen intestinal colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Real-time PCR quantification of bacterial adhesion to Caco-2 cells: competition between bifidobacteria and enteropathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Clinical efficacy of probiotics: review of the evidence with focus on children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Assessment of Mucosal Inflammation and Circulation in Response to Probiotics in Patients Operated with Ileal Pouch Anal Anastomosis for Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a J-configurated ileal-pouch-anal-anastomosis (IPAA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

A pilot trial of Saccharomyces boulardii in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Lactobacillus GG in inducing and maintaining remission of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Saccharomyces boulardii in maintenance treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Complementary and alternative medicine use by patients with inflammatory bowel disease: results from a postal survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Recommendations for probiotic use-2011 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-012-0265-5

Probiotics for maintenance of remission in Crohn's disease

21 January 2018

1 reference

12 December 2020

Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora

1 reference

12 December 2020

Probiotics for induction of remission in ulcerative colitis

1 reference

12 December 2020

Is Lactobacillus GG Helpful in Children With Crohn’s Disease? Results of a Preliminary, Open-Label Study

1 reference

12 December 2020

Antibiotics and probiotics in chronic pouchitis: a comparative proteomic approach.

1 reference

12 December 2020

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

1 reference

12 December 2020

Probiotics and remission of ulcerative colitis: a systematic review

1 reference

12 December 2020

Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?

1 reference

12 December 2020

Probiotics for induction of remission in Crohn's disease

1 reference

12 December 2020

Interventions for prevention of post-operative recurrence of Crohn's disease

1 reference

12 December 2020

Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment

1 reference

12 December 2020

Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults

1 reference

12 December 2020

Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles

1 reference

12 December 2020

The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis

1 reference

12 December 2020

Production of experimental ulcerative colitis in gnotobiotic guinea pigs with simplified microflora

1 reference

12 December 2020

Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum

1 reference

12 December 2020

Probiotics in the treatment of human inflammatory bowel diseases: update 2011.

1 reference

12 December 2020

Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)

1 reference

12 December 2020

Probiotics for maintenance of remission in ulcerative colitis

1 reference

12 December 2020

Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis

1 reference

12 December 2020

Inflammatory bowel disease: lessons from the IL-10 gene-deficient mouse

1 reference

12 December 2020

Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection

1 reference

12 December 2020

Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.

1 reference

12 December 2020

Probiotics, nuclear receptor signaling, and anti-inflammatory pathways

1 reference

12 December 2020

Probiotic use in clinical practice: what are the risks?

1 reference

12 December 2020

Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice

1 reference

12 December 2020

10.1007/S11894-012-0265-5

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1018375817

0 references

1 reference